AstraZeneca Plc continued to diversify its portfolio in 2022 with medicines for rare diseases contributing 16% of total revenue – the third largest component after oncology and drugs for cardiovascular and renal diseases. This followed the company’s $39 billion acquisition of Alexion Pharmaceuticals in July 2021, a deal that broadened its product profile and gave it a new footprint in the US. Work is underway to set up a new research site in Kendall Square, Cambridge, US, which would complement the company’s new facilities in Cambridge, UK.
